Standard
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. / Ascierto, Paolo A; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Zhukova, Natalia; Schachter, Jacob; Yan, Yibing; Caro, Ivor; Hertig, Christian; Xue, Cloris; Kusters, Lieke; McArthur, Grant A; Gutzmer, Ralf.
в:
The Lancet Oncology, Том 24, № 1, 01.01.2023, стр. 33-44.
Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Harvard
Ascierto, PA, Stroyakovskiy, D, Gogas, H, Robert, C, Lewis, K, Protsenko, S, Pereira, RP, Eigentler, T, Rutkowski, P, Demidov, L
, Zhukova, N, Schachter, J, Yan, Y, Caro, I, Hertig, C, Xue, C, Kusters, L, McArthur, GA & Gutzmer, R 2023, '
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study',
The Lancet Oncology, Том. 24, № 1, стр. 33-44.
https://doi.org/doi: 10.1016/S1470-2045(22)00687-8,
https://doi.org/10.1016/s1470-2045(22)00687-8APA
Ascierto, P. A., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L.
, Zhukova, N., Schachter, J., Yan, Y., Caro, I., Hertig, C., Xue, C., Kusters, L., McArthur, G. A., & Gutzmer, R. (2023).
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
The Lancet Oncology,
24(1), 33-44.
https://doi.org/doi: 10.1016/S1470-2045(22)00687-8,
https://doi.org/10.1016/s1470-2045(22)00687-8Vancouver
Author
Ascierto, Paolo A ; Stroyakovskiy, Daniil ; Gogas, Helen ; Robert, Caroline ; Lewis, Karl ; Protsenko, Svetlana ; Pereira, Rodrigo P ; Eigentler, Thomas ; Rutkowski, Piotr ; Demidov, Lev
; Zhukova, Natalia ; Schachter, Jacob ; Yan, Yibing ; Caro, Ivor ; Hertig, Christian ; Xue, Cloris ; Kusters, Lieke ; McArthur, Grant A ; Gutzmer, Ralf. /
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. в:
The Lancet Oncology. 2023 ; Том 24, № 1. стр. 33-44.
BibTeX
@article{ce8bdfdb30644863a7ae2d66e9d9c9f6,
title = "Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study",
author = "Ascierto, {Paolo A} and Daniil Stroyakovskiy and Helen Gogas and Caroline Robert and Karl Lewis and Svetlana Protsenko and Pereira, {Rodrigo P} and Thomas Eigentler and Piotr Rutkowski and Lev Demidov and Natalia Zhukova and Jacob Schachter and Yibing Yan and Ivor Caro and Christian Hertig and Cloris Xue and Lieke Kusters and McArthur, {Grant A} and Ralf Gutzmer",
year = "2023",
month = jan,
day = "1",
doi = "doi: 10.1016/S1470-2045(22)00687-8",
language = "English",
volume = "24",
pages = " 33--44",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",
}
RIS
TY - JOUR
T1 - Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
AU - Ascierto, Paolo A
AU - Stroyakovskiy, Daniil
AU - Gogas, Helen
AU - Robert, Caroline
AU - Lewis, Karl
AU - Protsenko, Svetlana
AU - Pereira, Rodrigo P
AU - Eigentler, Thomas
AU - Rutkowski, Piotr
AU - Demidov, Lev
AU - Zhukova, Natalia
AU - Schachter, Jacob
AU - Yan, Yibing
AU - Caro, Ivor
AU - Hertig, Christian
AU - Xue, Cloris
AU - Kusters, Lieke
AU - McArthur, Grant A
AU - Gutzmer, Ralf
PY - 2023/1/1
Y1 - 2023/1/1
U2 - doi: 10.1016/S1470-2045(22)00687-8
DO - doi: 10.1016/S1470-2045(22)00687-8
M3 - Article
VL - 24
SP - 33
EP - 44
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 1
ER -
